NEW YORK, July 19, 2026, 14:09 EDT – AtaiBeckley NASDAQ:ATAI stock traded as its Merger contingent value right (CVR) was priced at about 19% of its stated value.
- Shares ended Friday at $7.22, up 39.7% over the week.
- The $2.50 contingent payment is initially valued at $0.47 by the price.
- A 15.4% shareholder group has committed to back the takeover.
AtaiBeckley NASDAQ:ATAI, previously known as Atai Life Sciences, closed at $7.22 on Friday, trading 47 cents higher than the cash element of Eli Lilly’s NYSE:LLY offer. U.S. stock markets did not open on Sunday.
The gap assigns the contingent value right, or CVR, an initial value of $0.47, representing 18.8% of the $2.50 maximum payout. The calculation excludes time value, risks from the deal not closing, and the chance of a competing offer.
The majority of headline value is postponed. The initial $1 payment depends on VLS-01 advancing to Phase 3 in four years. Two subsequent payments are contingent on U.S. approvals and drug rescheduling.
| Comparison | Per share | Investor read-through |
|---|---|---|
| Closing price, July 15 | $5.36 | Baseline before the announcement |
| Cash paid at closing | $6.75 | 25.9% premium to baseline |
| Closing price, July 17 | $7.22 | $0.47 higher than the cash offer |
| Maximum CVR payout | $2.50 | Linked to three separate milestones |
| Highest potential total payment | $9.25 | 28.1% higher than Friday’s figure |
| Early implied CVR value | $0.47 | 18.8% of the potential maximum |
Figures are based on Friday’s regular-session closing price and stated deal terms. The implied value does not represent a milestone probability.
Atai advanced 39.7% last week, increasing from $5.17 to $7.22. In contrast, the Nasdaq Composite fell 2.9% over the same period. Atai closed at a 52-week high.
Trading activity was strong. On Thursday and Friday, 207.9 million shares changed hands, representing 56.5% of the shares outstanding. Shares can be traded multiple times.
Lilly anticipates completing the acquisition in the third quarter. The agreement is subject to approval from a majority of shareholders as well as regulatory clearance. There is no financing condition attached.
A regulatory filing released on Friday revealed a major voting bloc has already pledged support. Christian Angermayer and associated entities disclosed beneficial ownership of 15.4%. While they have entered agreements backing the merger, this stake alone does not provide majority control.
Barclays NYSE:BCS analyst Emily Field said the acquisition “offers upside potential in large markets like depression.” Jefferies Financial Group NYSE:JEF analyst Andrew Tsai stated that successful BPL-003 sales could top $1 billion, with a possible upside of $2 billion. Reuters
BPL-003 is administered intranasally for patients with treatment-resistant depression. The FDA has granted the therapy Breakthrough Therapy status. Phase 3 trials are underway, with preliminary data anticipated in early 2029.
The company intends to submit a shareholder proxy, though a vote date has yet to be scheduled. Investors are expected to monitor the filing and await regulatory approval. Nasdaq’s regular trading session resumes Monday at 9:30 a.m. EDT.
Risks: The closing may be delayed or may not occur. CVRs are expected to be unlisted and mostly non-transferable. Lilly is required to make commercially reasonable efforts, but is not obligated to increase or speed up payments.
Related articles: NASDAQ:ATAI
